Recursion Pharmaceuticals (RXRX) Set to Announce Quarterly Earnings on Thursday

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, May 9th. Analysts expect Recursion Pharmaceuticals to post earnings of ($0.43) per share for the quarter. Persons interested in listening to the company's earnings conference call can do so using this link.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its earnings results on Tuesday, February 27th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.06. Recursion Pharmaceuticals had a negative return on equity of 72.88% and a negative net margin of 735.99%. The firm had revenue of $10.89 million during the quarter, compared to analyst estimates of $12.37 million. On average, analysts expect Recursion Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Recursion Pharmaceuticals Price Performance

NASDAQ:RXRX traded up $0.05 during mid-day trading on Friday, reaching $8.84. The company's stock had a trading volume of 3,934,676 shares, compared to its average volume of 6,367,370. Recursion Pharmaceuticals has a twelve month low of $4.80 and a twelve month high of $16.75. The company's fifty day simple moving average is $9.97 and its two-hundred day simple moving average is $9.16. The stock has a market cap of $2.07 billion, a P/E ratio of -5.83 and a beta of 0.85.

Analysts Set New Price Targets

A number of research firms recently issued reports on RXRX. Needham & Company LLC restated a "buy" rating and issued a $17.00 target price on shares of Recursion Pharmaceuticals in a report on Tuesday, April 9th. KeyCorp upped their price objective on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the stock an "overweight" rating in a report on Monday, March 4th. Finally, TD Cowen began coverage on Recursion Pharmaceuticals in a report on Friday, January 26th. They issued a "market perform" rating on the stock. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $12.75.

Insider Buying and Selling at Recursion Pharmaceuticals

In other news, Director Blake Borgeson sold 11,447 shares of the stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $9.30, for a total value of $106,457.10. Following the completion of the sale, the director now owns 7,312,917 shares of the company's stock, valued at $68,010,128.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, COO Tina Marriott sold 8,000 shares of the firm's stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $14.89, for a total transaction of $119,120.00. Following the sale, the chief operating officer now directly owns 639,982 shares in the company, valued at approximately $9,529,331.98. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Blake Borgeson sold 11,447 shares of the business's stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $9.30, for a total value of $106,457.10. Following the transaction, the director now directly owns 7,312,917 shares in the company, valued at $68,010,128.10. The disclosure for this sale can be found here. Insiders have sold a total of 412,665 shares of company stock valued at $4,036,978 over the last ninety days. Corporate insiders own 19.96% of the company's stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.